2216 Stock Overview
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Broncus Holding Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$0.59 |
52 Week High | HK$1.97 |
52 Week Low | HK$0.58 |
Beta | 0.90 |
1 Month Change | -23.38% |
3 Month Change | -11.94% |
1 Year Change | -62.18% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -96.07% |
Recent News & Updates
We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully
Mar 21Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans
Nov 30Recent updates
We Think Broncus Holding (HKG:2216) Needs To Drive Business Growth Carefully
Mar 21Broncus Holding (HKG:2216) Is In A Good Position To Deliver On Growth Plans
Nov 30Will Broncus Holding (HKG:2216) Spend Its Cash Wisely?
May 31Companies Like Broncus Holding (HKG:2216) Are In A Position To Invest In Growth
Feb 27An Intrinsic Calculation For Broncus Holding Corporation (HKG:2216) Suggests It's 47% Undervalued
Dec 06Analysts Just Slashed Their Broncus Holding Corporation (HKG:2216) EPS Numbers
Sep 04Here's Why We're Not Too Worried About Broncus Holding's (HKG:2216) Cash Burn Situation
Jun 21Shareholder Returns
2216 | HK Medical Equipment | HK Market | |
---|---|---|---|
7D | -11.9% | -2.3% | -0.7% |
1Y | -62.2% | -48.6% | -13.4% |
Return vs Industry: 2216 underperformed the Hong Kong Medical Equipment industry which returned -48.6% over the past year.
Return vs Market: 2216 underperformed the Hong Kong Market which returned -13.4% over the past year.
Price Volatility
2216 volatility | |
---|---|
2216 Average Weekly Movement | 7.9% |
Medical Equipment Industry Average Movement | 7.9% |
Market Average Movement | 7.3% |
10% most volatile stocks in HK Market | 14.7% |
10% least volatile stocks in HK Market | 3.7% |
Stable Share Price: 2216's share price has been volatile over the past 3 months.
Volatility Over Time: 2216's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 314 | Hong Xu | https://www.broncus.com |
Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus/Archimedes Lite, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker that is used to mark the location of the lung nodule to achieve precise positioning during surgical pneumonectomy.
Broncus Holding Corporation Fundamentals Summary
2216 fundamental statistics | |
---|---|
Market cap | HK$311.05m |
Earnings (TTM) | -HK$208.88m |
Revenue (TTM) | HK$89.39m |
3.5x
P/S Ratio-1.5x
P/E RatioIs 2216 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2216 income statement (TTM) | |
---|---|
Revenue | US$11.43m |
Cost of Revenue | US$2.55m |
Gross Profit | US$8.88m |
Other Expenses | US$35.59m |
Earnings | -US$26.71m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 28, 2024
Earnings per share (EPS) | -0.051 |
Gross Margin | 77.69% |
Net Profit Margin | -233.68% |
Debt/Equity Ratio | 0.01% |
How did 2216 perform over the long term?
See historical performance and comparison